NOX Share Price History
23 Jul, 2020
Noxopharm has claimed a breakthrough in the search for restoring immune function within "cold" microtumors, converting them to so-called "hot" tumors.
14 May, 2020
Investing in stocks comes with the risk that the share price will fall. Anyone who held Noxopharm Limited (ASX:NOX...
25 Feb, 2020
The FDA has approved Noxopharm's IND application for Veyonda® for combination treatment with doxorubicin in patients with soft tissue sarcomas.
14 Feb, 2020
Noxopharm is pleased to announce positive interim results from its LuPIN Phase 1/2 clinical trial.
02 Dec, 2019
Clinical responses point to the NOX66 DARRT treatment regimen as a potentially major new treatment option for men with late-stage prostate cancerPositive results trigger.
06 Nov, 2019
Noxopharm has appointed Mr Alexander Hunter as Chief Commercial OfficerMr Hunter is an experienced corporate finance and business executive with a background in high growth.
22 Oct, 2019
It hasn't been the best quarter for Noxopharm Limited (ASX:NOX) shareholders, since the share price has fallen 12% in...
18 Oct, 2019
Noxopharm (NOX.AX) announces that it will apply its glutamate-inhibition technology to the treatment of glioblastoma multiforme (GBM). GBM remains a poorly managed cancer, with surgery, radiotherapy and the chemotherapy drug, temozolomide, the current standard of care, offering median survival of only 12-15 months.
30 Sep, 2019
On further review of the interim data, Noxopharm now sees an important and exciting story emerging that it considers needs to be brought to market attention. Noxopharm is developing Veyonda® as a drug to boost the effectiveness of two forms of radiation therapy in prostate cancer with the aim of relieving pain, decreasing the activity of the cancer and extending life. In one form, the radiation is delivered externally (DARRT study).
17 Sep, 2019
Noxopharm (NOX.AX) (‘Noxopharm’ or the ‘Company’) is pleased to announce that Australian clinicians will be presented updates on research relating to the use of Veyonda® (idronoxil) with radiotherapy for the treatment of prostate cancer at the Clinical Oncology Society of Australia (COSA) annual scientific meeting in November this year. This is the key meeting for oncologists in Australia and this year there is a program focus on urological cancer. The Company is releasing details of the presentations now as the meeting organisers have released the scientific abstracts earlier than expected via the meeting website.
28 Aug, 2019
Media Statement Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment Further Promising Results
The Company’s DARRT (Direct and Abscopal Response to Radiotherapy) Program is testing the ability of Veyonda® to increase tumour response to low-dose radiotherapy in prostate cancer. The Company previously reported on the patients in the dose-escalation or first part of the study on 2 May 2019. Dr Greg van Wyk, Noxopharm CEO and Chief Medical Officer, said: ‘Today’s data builds positively on the previously released figures obtained from the first group of patients living with end-stage metastatic castration-resistant prostate cancer (mCRPC).
21 Aug, 2019
Noxopharm Limited (NOX.AX) (‘Noxopharm’ or the ‘Company’) is pleased to provide an update on results from a series of key proof-of-principle experiments in mice that are exploring the interaction between Veyonda® and radiotherapy in a novel and potentially transformative treatment regimen known as DARRT (Direct and Abscopal Response to Radiotherapy). An abscopal response is where radiation directed at a tumour in one part of the body leads to an anti-cancer response both in the irradiated tumour as well as in tumours elsewhere in the body.